AZD3514|cas:1240299-33-5|西域试剂

AZD3514,99.32%

产品编号：Bellancom-16079| CAS NO：1240299-33-5| 分子式：C₂₅H₃₂F₃N₇O₂| 分子量：519.56

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	价格	库存与货期
Bellancom-16079	￥744.00	杭州北京（现货）
Bellancom-16079	￥1302.00	杭州北京（现货）
Bellancom-16079	￥3720.00	杭州北京（现货）
Bellancom-16079	￥6045.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

AZD3514

产品介绍

AZD3514 是一种具有口服活性的，选择性的 androgen receptor (AR) 抑制剂。AZD3514 雄性激素依赖的，以及非依赖的抑制 AR 信号。AZD351 在雄激素缺失的情况下下调 LNCaP 人前列腺癌细胞的核 AR 含量，其 pIC₅₀ 值为 5.75。AZD3514 可用于前列腺癌的研究。

生物活性

AZD3514 is an orally activie and selective androgen receptor (AR) inhibitor. AZD3514 androgen-dependently and -independently inhibits AR signal. AZD351 down-regulates nuclear AR levels in human LNCaP prostate cancer cells in the absence of androgen with an pIC₅₀ value of 5.75. AZD3514 can be used for the research of prostate cancer.

体外研究

AZD3514 (0-10 μM/L; 7 d) inhibits LNCaP and LAPC4 cells proliferation.
AZD3514 (0-10 μM/L; 24 h) inhibits the ligand-driven expression of known AR-regulated genes.
AZD3514 (0-30 μM/L; 24 h) reduces AR protein expression in LNCaPs and LAPC4s.
AZD3514 (1-10 μM/L; 2 h) reduces AR nuclear translocation in LNCaP cells.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Proliferation Assay

Cell Line:	LNCaP and LAPC4 cell lines
Concentration:	0, 0.1, 0.4, 1.1, 3.3 and 10 μM/L
Incubation Time:	7 days
Result:	Inhibited LAPC4 cells growth and dose-dependently inhibited proliferation of LNCaP cells.

Western Blot Analysis

Cell Line:	LNCaP and LAPC4 cell lines
Concentration:	0, 0.4, 1.1, 3.3, 10 and 30 μM/L
Incubation Time:	0-24 hours
Result:	Dose-dependently reduced AR protein expression in LNCaPs, and decreased AR protein in LAPC4 cells with a concentration of 10 μM/L. Reduced the rate of AR synthesis to reduce the concentration of AR protein.

RT-PCR

Cell Line:	LNCaP and LAPC4 cell lines
Concentration:	0, 0.4, 1.1, 3.3 and 10 μM/L
Incubation Time:	24 hours
Result:	Inhibited ligand-driven expression of AR-regulated genes PSA and TMPRSS2 in both LNCaP and LAPC4 cells.

体内研究
(In Vivo)

AZD3514 (10-100 mg/kg; p.o. once daily for 6 days) inhibits AR signaling in rats.
AZD3514 (50 mg/kg; p.o. once daily for 30 days) inhibits prostate tumor growth.
AZD3514 (50-100 mg/kg; p.o. once daily for 3 days) significantly reduces nuclear AR protein in vivo.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Intact or castrat 42- and 49-day-old Hans Wistar rats
Dosage:	10, 50 and 100 mg/kg
Administration:	Oral gavage; 10-100 mg/kg once daily; for 6 days
Result:	Inhibited AR signaling in rats, reduced seminal vesicle weight in intact rats, and inhibited the ability of exogenous testosterone proprionate to cause an increase in seminal vesicle weight in castrated rat.

Animal Model:	Male Copenhagen rats with Dunning R3327H prostate tumors
Dosage:	50 mg/kg
Administration:	Oral gavage; 50 mg/kg once daily; for 30 days
Result:	Significantly inhibited prostate tumor growth of rats.

体内研究

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Intact or castrat 42- and 49-day-old Hans Wistar rats
Dosage:	10, 50 and 100 mg/kg
Administration:	Oral gavage; 10-100 mg/kg once daily; for 6 days
Result:	Inhibited AR signaling in rats, reduced seminal vesicle weight in intact rats, and inhibited the ability of exogenous testosterone proprionate to cause an increase in seminal vesicle weight in castrated rat.

Animal Model:	Male Copenhagen rats with Dunning R3327H prostate tumors
Dosage:	50 mg/kg
Administration:	Oral gavage; 50 mg/kg once daily; for 30 days
Result:	Significantly inhibited prostate tumor growth of rats.

体内研究

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Intact or castrat 42- and 49-day-old Hans Wistar rats
Dosage:	10, 50 and 100 mg/kg
Administration:	Oral gavage; 10-100 mg/kg once daily; for 6 days
Result:	Inhibited AR signaling in rats, reduced seminal vesicle weight in intact rats, and inhibited the ability of exogenous testosterone proprionate to cause an increase in seminal vesicle weight in castrated rat.

Animal Model:	Male Copenhagen rats with Dunning R3327H prostate tumors
Dosage:	50 mg/kg
Administration:	Oral gavage; 50 mg/kg once daily; for 30 days
Result:	Significantly inhibited prostate tumor growth of rats.

性状

Solid

溶解性数据

In Vitro:

DMSO : ≥ 100 mg/mL (192.47 mM)

* "≥" means soluble, but saturation unknown.

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	1.9247 mL	9.6235 mL	19.2471 mL
5 mM	0.3849 mL	1.9247 mL	3.8494 mL
10 mM	0.1925 mL	0.9624 mL	1.9247 mL

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

1.

请依序添加每种溶剂： 10% DMSO 40% PEG300 5% Tween-80 45% saline
Solubility: ≥ 2.5 mg/mL (4.81 mM); Clear solution

此方案可获得 ≥ 2.5 mg/mL (4.81 mM，饱和度未知) 的澄清溶液。
以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。
将 0.9 g 氯化钠，完全溶解于 100 mL ddH₂O 中，得到澄清透明的生理盐水溶液
2.

请依序添加每种溶剂： 10% DMSO 90% (20% SBE-β-CD in saline)
Solubility: ≥ 2.5 mg/mL (4.81 mM); Clear solution

此方案可获得 ≥ 2.5 mg/mL (4.81 mM，饱和度未知) 的澄清溶液。
以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。
将 2 g 磺丁基醚 β-环糊精加入 5 mL 生理盐水中，再用生理盐水定容至 10 mL，完全溶解，澄清透明
3.

请依序添加每种溶剂： 10% DMSO 90% corn oil
Solubility: ≥ 2.5 mg/mL (4.81 mM); Clear solution

此方案可获得 ≥ 2.5 mg/mL (4.81 mM，饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。
以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。